Other News To Note
Wednesday, October 3, 2012
Amakem NV, of Diepenbeek, Belgium, initiated a Phase IIa proof-of-concept study of its Rho kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.